Although CCL2/MCP-1 exhibited significantly lower plasma levels in patients with glomerular diseases (237.6 ± 110.5 pg/mL; n = 36) compared to healthy subjects (341.5 ± 112.6 pg/mL; p < 0.01; n = 31), there was no difference between patients with FSGS recurrence after kidney transplantation (266.9 ± 118.0 pg/mL; n = 6) and those with glomerular diseases or healthy subjects (p = 0.64 and p = 0.21, respectively) (Figure 4). Here, CCL2 is linked to focal segmental glomerulosclerosis.